Zenas BioPharma (ZBIO) Fundamental Analysis: Revenue, Earnings & Valuation

8.37 / 10

Outperform

Fundamental metrics rate ZBIO as Outperform with an 8.37 score. Strengths include strong interest coverage, solid PB‑ROE, high inventory turnover and 100% YoY revenue growth. Weaknesses are a high current‑liabilities ratio and negative revenue‑to‑market value. Overall fundamentals are robust.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score1/3

Weight18.17%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value100.00

Score2/3

Weight0.50%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.17%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value44.28

Score0/3

Weight-15.46%

1M Return-4.96%

PB-ROE

Value2.89

Score3/3

Weight46.07%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.27

Score2/3

Weight-1.29%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.24%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value100.00

Score2/3

Weight0.20%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.01%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight64.22%

1M Return11.61%

Is ZBIO undervalued or overvalued?

ZBIO scores 8.37/10 on fundamentals and holds a Discounted valuation at present. Backed by its -136.22% ROE, -3777.37% net margin, -3.36 P/E ratio, 5.24 P/B ratio, and 29.02% earnings growth, these metrics solidify its Outperform investment rating.